|
Market Closed -
London S.E.
03:35:21 07/11/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 1.000 GBX | -4.76% |
|
+11.11% | -47.37% |
| 04/11 | WINNERS & LOSERS: Forgent gets better deal terms, Synergia has delay | AN |
| 03/11 | WINNERS & LOSERS: Allergy Therapeutics shares plunge on AIM exit plan | AN |
| Market Cap | 2.16M 2.88M 2.59M 2.36M 4.07M 271M 4.19M 28.5M 11.36M 145M 10.83M 10.59M 457M | P/E 2024 |
-2.47x | P/E 2025 | -3.56x |
|---|---|---|---|---|---|
| Enterprise Value | 2.01M 2.69M 2.41M 2.2M 3.79M 252M 3.9M 26.53M 10.58M 135M 10.08M 9.86M 425M | EV / Sales 2024 |
61,809,222x | EV / Sales 2025 | 76,138,323x |
| Free-Float |
81.3% | Yield 2024 * |
-
| Yield 2025 | - |
London S.E.GBX
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| BSFA | Delayed | |
OTC Markets
| BSFAF | Delayed |
| 07/02 | BSF : Proxy Form | PU |
| 07/02 | BSF : Notice of AGM | PU |
| 07/03/25 | BSF : Publication of Prospectus | PU |
| 07/03/25 | BSF : Prospectus | PU |
| 08/02/25 | BSF : Proxy Form | PU |
| 1 day | -4.76% | ||
| 1 week | +11.11% | ||
| Current month | +11.11% | ||
| 1 month | -11.11% | ||
| 3 months | +11.11% | ||
| 6 months | -46.67% | ||
| Current year | -47.37% |
| 1 week | 0.88 |  | 1.3 |
| 1 month | 0.8 | | 1.3 |
| Current year | 0.5 | | 4 |
| 1 year | 0.5 | | 4 |
| 3 years | 0.5 | | 12.45 |
| 5 years | 0.5 | | 23.88 |
| 10 years | 0.5 | | 23.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Che Connon
CEO | Chief Executive Officer | 54 | - |
Graham Duncan
DFI | Director of Finance/CFO | 62 | 06/06/2022 |
Ricardo Gouveia
PRN | Corporate Officer/Principal | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Geoffrey Baker
CHM | Chairman | 70 | 05/12/2025 |
Kian Jing Ow
BRD | Director/Board Member | 60 | 05/08/2021 |
Che Connon
BRD | Director/Board Member | 54 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 18/6/24 | Buy | Chief Financial Officer | 500 | 0.0005% | ||
| 18/6/24 | Buy | Chief Financial Officer | 11,798 | 0.0114% | ||
| 18/6/24 | Buy | Chief Financial Officer | 23,500 | 0.0227% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.76% | +11.11% | -65.52% | -87.50% | 2.71M | |
| -0.19% | -3.86% | +45.38% | +128.98% | 1,216B | |
| +1.09% | +0.85% | +47.36% | +81.62% | 656B | |
| +0.66% | -1.64% | +32.42% | +105.41% | 509B | |
| -0.36% | -3.25% | +47.17% | +64.58% | 384B | |
| -0.25% | -1.95% | +70.91% | +40.51% | 362B | |
| -0.78% | -0.52% | +30.57% | +57.98% | 311B | |
| -0.80% | -0.21% | +8.54% | +35.56% | 293B | |
| +0.13% | -1.05% | +46.12% | +69.02% | 249B | |
| +0.01% | -1.81% | +35.81% | +106.54% | 208B | |
| Average | -0.63% | +1.94% | +29.88% | +60.27% | 418.78B | |
| Weighted average by Cap. | -0.08% | -0.18% | +42.37% | +88.65% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 0.06 0.08 0.07 0.06 0.11 7.26 0.11 0.76 0.3 3.88 0.29 0.28 12.24 | 0.05 0.07 0.06 0.06 0.1 6.64 0.1 0.7 0.28 3.54 0.27 0.26 11.18 |
| Net income | -1.67M -2.23M -2M -1.83M -3.15M -210M -3.25M -22.08M -8.8M -112M -8.39M -8.21M -354M | -1.11M -1.49M -1.33M -1.22M -2.1M -140M -2.16M -14.7M -5.86M -74.64M -5.59M -5.47M -236M |
| Net Debt | -560K -748K -671K -613K -1.05M -70.3M -1.09M -7.39M -2.95M -37.51M -2.81M -2.75M -118M | -149K -199K -179K -163K -281K -18.72M -290K -1.97M -785K -9.99M -748K -732K -31.54M |
Employees
14
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/11/26 | GBX 1.000 | -4.76% | 871,488 |
| 05/11/26 | GBX 1.050 | -10.64% | 7,099,895 |
| 04/11/26 | GBX 1.175 | +30.56% | 15,230,954 |
| 03/11/26 | GBX 0.9000 | -5.26% | 988,698 |
| 02/11/26 | GBX 0.9500 | +5.56% | 7,449,597 |
- Stock Market
- Stocks
- BSFA Stock
Select your edition
All financial news and data tailored to specific country editions
